{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T06:01:31Z","timestamp":1720072891706},"reference-count":38,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2006,11,1]],"date-time":"2006-11-01T00:00:00Z","timestamp":1162339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2006,11]]},"DOI":"10.1016\/j.leukres.2006.03.004","type":"journal-article","created":{"date-parts":[[2006,4,20]],"date-time":"2006-04-20T12:05:47Z","timestamp":1145534747000},"page":"1377-1384","source":"Crossref","is-referenced-by-count":20,"title":["Induction of apoptosis and down regulation of cell cycle proteins in mantle cell lymphoma by flavopiridol treatment"],"prefix":"10.1016","volume":"30","author":[{"given":"Girish","family":"Venkataraman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tazeen","family":"Maududi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fulya","family":"OzPuyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hakki I.","family":"Bahar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith F.","family":"Izban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiang-Zon","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serhan","family":"Alkan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2006.03.004_bib1","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s11864-003-0023-x","article-title":"Mantle cell lymphoma: therapeutic strategies are different from CLL","volume":"4","author":"Hiddemann","year":"2003","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.leukres.2006.03.004_bib2","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1200\/JCO.1999.17.12.3835","article-title":"World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997","volume":"17","author":"Harris","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2006.03.004_bib3","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1365-2141.1991.tb08582.x","article-title":"Non-Hodgkin's lymphomas with t(11;14)(q13;q32): a subset of mantle zone\/intermediate lymphocytic lymphoma?","volume":"77","author":"Leroux","year":"1991","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2006.03.004_bib4","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/oxfordjournals.annonc.a058904","article-title":"European lymphoma task force (ELTF): report of the workshop on mantle cell lymphoma (MCL)","volume":"5","author":"Zucca","year":"1994","journal-title":"Ann Oncol"},{"key":"10.1016\/j.leukres.2006.03.004_bib5","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature03094","article-title":"G1 cell-cycle control and cancer","volume":"432","author":"Massague","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2006.03.004_bib6","first-page":"69","article-title":"Assays for cyclin-dependent kinase inhibitors","volume":"285","author":"Senderowicz","year":"2004","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.leukres.2006.03.004_bib7","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0163-7258(98)00062-X","article-title":"Cyclin-dependent kinases: initial approaches to exploit a novel therapeutic target","volume":"82","author":"Sausville","year":"1999","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.leukres.2006.03.004_bib8","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1749-6632.2000.tb06710.x","article-title":"Inhibition of CDKs as a therapeutic modality","volume":"910","author":"Sausville","year":"2000","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.leukres.2006.03.004_bib9","first-page":"4634","article-title":"Down regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol","volume":"59","author":"Carlson","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2006.03.004_bib10","first-page":"4856","article-title":"Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells","volume":"56","author":"Bible","year":"1996","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2006.03.004_bib11","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood.V96.2.393","article-title":"Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia","volume":"96","author":"Kitada","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2006.03.004_bib12","doi-asserted-by":"crossref","first-page":"4307","DOI":"10.1182\/blood.V90.11.4307","article-title":"The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines","volume":"90","author":"Konig","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2006.03.004_bib13","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0145-2126(01)00103-5","article-title":"Growth inhibition and apoptosis of myeloma cells by the CDK inhibitor flavopiridol","volume":"26","author":"Semenov","year":"2002","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2006.03.004_bib14","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1182\/blood.V91.2.458","article-title":"Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol","volume":"91","author":"Parker","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2006.03.004_bib15","first-page":"2482","article-title":"Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts","volume":"91","author":"Arguello","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2006.03.004_bib16","doi-asserted-by":"crossref","first-page":"3804","DOI":"10.1182\/blood.V92.10.3804","article-title":"Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53","volume":"92","author":"Byrd","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2006.03.004_bib17","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1053\/j.seminhematol.2004.05.004","article-title":"Advances in chemotherapy for chronic lymphocytic leukemia","volume":"41","author":"Wendtner","year":"2004","journal-title":"Semin Hematol"},{"key":"10.1016\/j.leukres.2006.03.004_bib18","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1200\/JCO.1998.16.9.2986","article-title":"Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms","volume":"16","author":"Senderowicz","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2006.03.004_bib19","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1046\/j.1365-2141.1998.00911.x","article-title":"Establishment and characterization of a mantle cell lymphoma cell line","volume":"102","author":"Jeon","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2006.03.004_bib20","doi-asserted-by":"crossref","first-page":"424","DOI":"10.5858\/2003-127-0424-COMCLC","article-title":"Characterization of 4 mantle cell lymphoma cell lines","volume":"127","author":"Amin","year":"2003","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.leukres.2006.03.004_bib21","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0022-1759(97)00138-5","article-title":"Strategies for phenotyping apoptotic peripheral human lymphocytes comparing ISNT, annexin-V and 7-AAD cytofluorometric staining methods","volume":"209","author":"Lecoeur","year":"1997","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.leukres.2006.03.004_bib22","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1046\/j.1365-2141.2001.03102.x","article-title":"Analysis of expression of nuclear factor kappa B (NF-kappa B) in multiple myeloma: downregulation of NF-kappa B induces apoptosis","volume":"115","author":"Ni","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2006.03.004_bib23","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0022-1759(95)00072-I","article-title":"A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V","volume":"184","author":"Vermes","year":"1995","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.leukres.2006.03.004_bib24","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/jnci\/92.5.376","article-title":"Preclinical and clinical development of cyclin-dependent kinase modulators","volume":"92","author":"Senderowicz","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.leukres.2006.03.004_bib25","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/nrm1493","article-title":"Checking on DNA damage in S phase","volume":"5","author":"Bartek","year":"2004","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.leukres.2006.03.004_bib26","first-page":"2973","article-title":"Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells","volume":"56","author":"Carlson","year":"1996","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2006.03.004_bib27","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/01.cad.0000127332.06439.47","article-title":"Flavopiridol: pleiotropic biological effects enhance its anti-cancer activity","volume":"15","author":"Newcomb","year":"2004","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.leukres.2006.03.004_bib28","doi-asserted-by":"crossref","first-page":"11617","DOI":"10.1074\/jbc.R100063200","article-title":"Signaling networks that link cell proliferation and cell fate","volume":"277","author":"Sears","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.leukres.2006.03.004_bib29","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1182\/blood.V94.2.765","article-title":"Anomalous high p27\/KIP1 expression in a subset of aggressive B-cell lymphomas is associated with cyclin D3 overexpression. p27\/KIP1-cyclin D3 colocalization in tumor cells","volume":"94","author":"Sanchez-Beato","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2006.03.004_bib30","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1038\/sj.leu.2403139","article-title":"Flavopiridol downregulates the expression of both the inducible NO synthase and p27(kip1) in malignant cells from B-cell chronic lymphocytic leukemia","volume":"17","author":"Billard","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2006.03.004_bib31","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/366704a0","article-title":"A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D\/CDK4","volume":"366","author":"Serrano","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2006.03.004_bib32","doi-asserted-by":"crossref","first-page":"4122","DOI":"10.1158\/0008-5472.CAN-03-2519","article-title":"The inhibitor of cyclin-dependent kinase 4a\/alternative reading frame (INK4a\/ARF) locus encoded proteins p16INK4a and p19ARF repress cyclin D1 transcription through distinct cis elements","volume":"64","author":"D\u2019Amico","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2006.03.004_bib33","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1006\/scdb.2000.0165","article-title":"Proteolytic regulation of apoptosis","volume":"11","author":"Kidd","year":"2000","journal-title":"Semin Cell Dev Biol"},{"key":"10.1016\/j.leukres.2006.03.004_bib34","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/0092-8674(95)90422-0","article-title":"Protease activation during apoptosis: death by a thousand cuts?","volume":"82","author":"Martin","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.leukres.2006.03.004_bib35","first-page":"1681","article-title":"Mechanisms of glucocorticoid-mediated apoptosis in hematological malignancies","volume":"8","author":"Greenstein","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2006.03.004_bib36","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0092-8674(00)81334-3","article-title":"Human ICE\/CED-3 protease nomenclature","volume":"87","author":"Alnemri","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.leukres.2006.03.004_bib37","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/0092-8674(95)90541-3","article-title":"Yama\/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase","volume":"81","author":"Tewari","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.leukres.2006.03.004_bib38","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1158\/1535-7163.1513.3.12","article-title":"The small-molecule Bcl-2 inhibitor HA14-1 interacts synergistically with flavopiridol to induce mitochondrial injury and apoptosis in human myeloma cells through a free radical-dependent and Jun NH2-terminal kinase-dependent mechanism","volume":"3","author":"Pei","year":"2004","journal-title":"Mol Cancer Ther"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521260600107X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521260600107X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,7]],"date-time":"2023-05-07T04:30:22Z","timestamp":1683433822000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014521260600107X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2006,11]]}},"alternative-id":["S014521260600107X"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2006.03.004","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2006,11]]}}}